05 Mar 2025 By David Wild
Companies are exploring new mechanisms of action beyond traditional amyloid and tau and both investors and big pharma are willing to make deals when the science is compelling, panelists at Biotech Showcase said.
https://acrobat.adobe.com/id/urn:aaid:sc:va6c2:fb1f0c49-3601-4332-80f8-04cff5e71ead